Elinzanetant

Elinzanetant is a nonsteroidal selective neurokinin-1 receptor (NK1R) antagonist. It is being investigated for its potential use in the treatment of various conditions, including hot flashes and other symptoms associated with menopause.

Mechanism of Action

Elinzanetant works by selectively blocking the neurokinin-1 receptor, which is involved in the regulation of various physiological processes. By inhibiting this receptor, elinzanetant can modulate the activity of substance P, a neuropeptide associated with pain perception, stress, and inflammation.

Clinical Uses

Elinzanetant is primarily being studied for its effectiveness in treating vasomotor symptoms such as hot flashes and night sweats that are commonly experienced during menopause. These symptoms are thought to be mediated by the central nervous system and are influenced by the activity of neurokinin B and its receptors.

Research and Development

Elinzanetant is currently undergoing clinical trials to evaluate its safety and efficacy. Preliminary results have shown promise in reducing the frequency and severity of hot flashes in menopausal women. Further studies are needed to confirm these findings and to explore other potential therapeutic applications.

Side Effects

As with any medication, elinzanetant may cause side effects. Common side effects observed in clinical trials include nausea, headache, and fatigue. More serious side effects are rare but may include allergic reactions and cardiovascular issues.

See Also

• Neurokinin-1 receptor
• Menopause
• Hot flashes
• Substance P

External Links

-